Development and validation of an HPLC method for determination of carbamazepine in human plasma and applications to a therapeutic drug monitoring study

Basit Öğe Kaydı
dc.authoridDural, Emrah/0000-0002-9320-8008
dc.contributor.authorDural, Emrah
dc.contributor.authorCetin, Suleyman
dc.contributor.authorBolayir, Asli
dc.contributor.authorCigdem, Burhanettin
dc.date.accessioned2024-10-26T18:00:10Z
dc.date.available2024-10-26T18:00:10Z
dc.date.issued2020
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractBackground and Aims: Carbamazepine (CBZ) is an antiepileptic drug, which is prescribed as a first-line drug for the treatment of partial and generalized tonic-clonic epileptic seizures. The aim of this study was to develop and validate a simple, fast and reliable HPLC method for the determination of carbamazepine in human plasma. Methods: Chlorpromazine (CPR) was used as an internal standard. The separation was conducted with a C18 reverse-phase column (150x3.9 mm, 5 mu m) at 30 degrees C, using a mobile phase prepared with 20 mM KH2PO4, acetonitrile and methanol (6:3:1, v/v/v) by isocratic elution. Results: The method was linear between 0.5 and 40 mu g/mL, determined by 10 individual calibration points. Total run time was <= 5 mins. Accuracy (RE%) values were determined between (-5.6) and 3.6%, and precision was determined at <= 4.2%. Limit of detection (LOD) was 0.04 mu g/mL. The robustness test results of the method showed good values. Plasma CBZ of (n=30) those receiving CBZ quantities ranging from 0.2 to 1.2 g/day were measured with this method, and following analyses of their concentrations were found to be between 0.1 and 11.4 mu g/mL (6.2 +/- 2.4 mu g/mL). While all plasma sample analyses were applied properly, it was observed that 16 (53.3%) of the plasma samples had CBZ lower than the recommended range. In addition to that, female patient plasma-CBZ levels were found significantly higher than male plasma contents (p<0.05). Conclusion: This method was found suitable for the analysis of plasma samples collected during the therapeutic drug monitoring (TDM) of patients treated with CBZ.
dc.identifier.doi10.26650/IstanbulJPharm.2019.0054
dc.identifier.endpage15
dc.identifier.issn2587-2087
dc.identifier.issue1
dc.identifier.startpage6
dc.identifier.trdizinid379838
dc.identifier.urihttps://doi.org/10.26650/IstanbulJPharm.2019.0054
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/379838
dc.identifier.urihttps://hdl.handle.net/20.500.12418/27561
dc.identifier.volume50
dc.identifier.wosWOS:000523300100002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherIstanbul Univ, Fac Pharmacy
dc.relation.ispartofIstanbul Journal of Pharmacy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCarbamazepine
dc.subjectplasma
dc.subjecttherapeutic drug monitoring
dc.subjectvalidation
dc.subjecthigh-performance liquid chromatography
dc.subjectultraviolet detection
dc.titleDevelopment and validation of an HPLC method for determination of carbamazepine in human plasma and applications to a therapeutic drug monitoring study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu